233 related articles for article (PubMed ID: 25029934)
1. Other PET tracers for neuroendocrine tumors.
Koopmans KP; Glaudemans AW
PET Clin; 2014 Jan; 9(1):57-62. PubMed ID: 25029934
[TBL] [Abstract][Full Text] [Related]
2. Single-photon emission computed tomography tracers in the diagnostics of neuroendocrine tumors.
Pepe G; Bombardieri E; Lorenzoni A; Chiti A
PET Clin; 2014 Jan; 9(1):11-26. PubMed ID: 25029930
[TBL] [Abstract][Full Text] [Related]
3. [Contemporary nuclear medicine diagnostics of neuroendocrine tumors].
Srp Arh Celok Lek; 2015; 143(1-2):108-15. PubMed ID: 25845263
[TBL] [Abstract][Full Text] [Related]
4. 18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors.
Minn H; Kemppainen J; Kauhanen S; Forsback S; Seppänen M
PET Clin; 2014 Jan; 9(1):27-36. PubMed ID: 25029931
[TBL] [Abstract][Full Text] [Related]
5. Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors.
Panagiotidis E; Bomanji J
PET Clin; 2014 Jan; 9(1):43-55. PubMed ID: 25029933
[TBL] [Abstract][Full Text] [Related]
6. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography.
Koopmans KP; Neels OC; Kema IP; Elsinga PH; Sluiter WJ; Vanghillewe K; Brouwers AH; Jager PL; de Vries EG
J Clin Oncol; 2008 Mar; 26(9):1489-95. PubMed ID: 18349401
[TBL] [Abstract][Full Text] [Related]
7. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
[TBL] [Abstract][Full Text] [Related]
8. Imaging of neuroendocrine tumors.
Rufini V; Calcagni ML; Baum RP
Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
[TBL] [Abstract][Full Text] [Related]
9. Nuclear medicine imaging of neuroendocrine tumours.
Bombardieri E; Maccauro M; De Deckere E; Savelli G; Chiti A
Ann Oncol; 2001; 12 Suppl 2():S51-61. PubMed ID: 11762353
[TBL] [Abstract][Full Text] [Related]
10. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
[TBL] [Abstract][Full Text] [Related]
11. Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP).
Ambrosini V; Morigi JJ; Nanni C; Castellucci P; Fanti S
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):58-69. PubMed ID: 25677589
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: potential role of other positron emission tomography radiotracers.
Jadvar H
Semin Nucl Med; 2012 Jul; 42(4):247-54. PubMed ID: 22681673
[TBL] [Abstract][Full Text] [Related]
13. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
[TBL] [Abstract][Full Text] [Related]
14. Is 18F-Fluorodeoxyglucose the Tracer of Choice for Functional Imaging of Neuroendocrine Tumors Grade 3? A Case Report.
Lorusso M; Inzani F; Castaldi P; Menghi R; Schinzari G; Rindi G; Rufini V
Pancreas; 2018 Apr; 47(4):e20-e22. PubMed ID: 29521949
[No Abstract] [Full Text] [Related]
15. PET-Based Molecular Imaging in Designing Personalized Management Strategy in Gastroenteropancreatic Neuroendocrine Tumors.
Basu S; Ranade R; Ostwal V; Shrikhande SV
PET Clin; 2016 Jul; 11(3):233-41. PubMed ID: 27321028
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors.
Orlefors H; Sundin A; Ahlström H; Bjurling P; Bergström M; Lilja A; Långström B; Oberg K; Eriksson B
J Clin Oncol; 1998 Jul; 16(7):2534-41. PubMed ID: 9667275
[TBL] [Abstract][Full Text] [Related]
17. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography.
Orlefors H; Sundin A; Garske U; Juhlin C; Oberg K; Skogseid B; Langstrom B; Bergstrom M; Eriksson B
J Clin Endocrinol Metab; 2005 Jun; 90(6):3392-400. PubMed ID: 15755858
[TBL] [Abstract][Full Text] [Related]
18. Divergent role of (68)Ga-labeled somatostatin analogs in the workup of patients with NETs: AIIMS experience.
Naswa N; Bal CS
Recent Results Cancer Res; 2013; 194():321-51. PubMed ID: 22918767
[TBL] [Abstract][Full Text] [Related]
19. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
[TBL] [Abstract][Full Text] [Related]
20. Nuclear imaging of neuroendocrine tumours.
Sundin A; Garske U; Orlefors H
Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):69-85. PubMed ID: 17382266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]